Norfolk County Council's E-Cigarette Program Helps Smokers Quit

Aug.19.2022
Norfolk County Council's E-Cigarette Program Helps Smokers Quit
Norfolk County Council's pilot program offers free e-cigarette starter kits to smokers with over 42% successfully quitting smoking.

Norfolk County Council aims to help people quit smoking by launching a pilot program for e-cigarettes. Over 60% of the smokers who redeemed coupons for free e-cigarette starter kits were able to quit smoking within a month. Many smokers in Norfolk have failed to quit in the past, and as part of the trial, they were referred to professional smoking cessation services and offered a £25 voucher to exchange for an e-cigarette starter kit.


The program initially targeted patients from the city of Exeter, who were referred by general practitioners, self-referred, or referred through other healthcare providers.


People have been given advice and support and have been asked to cover the ongoing cost of using e-cigarettes. From December 2019 to July 2021, a total of 668 participants were referred to the program, with 340 people redeeming vouchers for e-cigarette starter kits. Out of the 340 people who redeemed the vouchers, 143 individuals (42%) quit smoking four weeks prior. A pilot program in Norfolk recorded that 42% of smokers quit smoking four weeks after using the vouchers to obtain a free e-cigarette starter kit.


A pilot program in Norfolk has found that 42% of smokers who received a free starter kit for electronic cigarettes using vouchers had quit smoking after four weeks. The average age of those referred to the program was 41.4 years old. Funded by the Norfolk County Council, the program has been expanded throughout the county with hopes of national implementation to aid more smokers in quitting. Professor Caitlin Notley, Chief Investigator at the Norwich Medical School at the University of East Anglia (UEA), stated that "research suggests that electronic cigarettes are an effective method for quitting smoking compared to nicotine replacement therapies such as patches and gum.


Electronic cigarettes or e-cigarettes are now the most popular method for quitting smoking. Previous research suggests they may be particularly helpful in assisting people to quit smoking for good. We wanted to see if offering e-cigarette shop vouchers and support for smoking cessation services from general practitioners could help smokers quit. We specifically wanted to target vulnerable and disadvantaged smokers who have been unable to quit by other means. "This program helped 42% of entrenched smokers quit within four weeks of redeeming their voucher, which is particularly important as it helps those who have tried to quit multiple times to move away from tobacco. Overall, the program has been well received by smokers since it provides an affordable pathway to e-cigarettes. General practitioners support the program and appreciate the alternatives it provides entrenched smokers.


The study titled "Pilot E-cigarette Voucher Scheme in Rural English Counties" was commissioned by Norfolk County Council and led by the University of East Anglia. Researchers collaborated with public health teams and local smoking cessation service Smokefree Norfolk. The study was published in the Nicotine and Tobacco Research journal.


Statement


This article is compiled from third-party information and is intended for educational purposes within the industry.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the article's content. The compilation of this article is only for industry communication and research purposes.


Due to limitations in translation abilities, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


In regards to any domestic, Hong Kong, Macau, Taiwan, and foreign statements and positions, 2FIRSTS aligns completely with the Chinese government.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
AIR’s first half-year results as a listed company offer a new test of how far a traditional hookah business can transform. H1 2026 revenue rose 3.7%, even as Flavored Shisha Molasses shipments fell 9%, with pricing and mix supporting growth. Traditional shisha still generates almost all revenue, while OOKA, Crown Switch, Greentank and U.S. regulatory spending point to accelerating diversification. The next test is whether those investments can become a second business of meaningful scale and profitability.
Capital Markets
Aug.21
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16